Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05089019 · ClinicalTrials.gov registry record · Phase 1
A Study Comparing Two Formulations of Selpercatinib (LY3527723) in Healthy Participants
A Phase 1 study, sponsored by Loxo Oncology.
- Completed
- Registry status
- Phase 1
- Development phase
- 224
- Enrollment target
NCT05089019: Completed Phase 1 study, sponsored by Loxo Oncology.
NCT05089019 is a Phase 1 study that has completed, run by Loxo Oncology. The registered enrollment target is 224 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (273% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05089019, a Phase 1 study, has completed, sponsored by Loxo Oncology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 224 participants
- Enrollment target
Study Summary
The main purpose of this study is to compare the amount of selpercatinib that gets into the blood stream and how long it takes the body to get rid of it, when given as different formulations. The information about any adverse effects experienced will be collected and the tolerability of selpercatinib will also be evaluated. The study may last up to 56 days including the 28 days of screening period.
Primary Outcome
PK: Cmax of Selpercatinib
Interventions
- DRUG Selpercatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 224 participants |
| Start Date | 2021-10-29 |
| Est. Completion | 2022-07-19 |
| Phase | Phase 1 |
What the finished NCT05089019 record still lists
NCT05089019 is an interventional study that assigns participants to a tested intervention. The registered 224 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (273% higher).
The record links to 0 conditions, and to 1 intervention - of which Selpercatinib is the first listed.
NCT05089019 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05089019 about?
NCT05089019 is a clinical study titled "A Study Comparing Two Formulations of Selpercatinib (LY3527723) in Healthy Participants". The main purpose of this study is to compare the amount of selpercatinib that gets into the blood stream and how long it takes the body to get rid of it, when given as different formulations. The information about any adverse effects experienced will be collected and the tolerability of selpercatini...
What is the current status of trial NCT05089019?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 224 participants. The study started on 2021-10-29. Estimated completion is 2022-07-19.
What interventions are being tested in trial NCT05089019?
The interventions under investigation include: Selpercatinib (DRUG).
Who is sponsoring clinical trial NCT05089019?
This trial is sponsored by Loxo Oncology, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05089019's enrollment target sits among peer trials
224 227th of 2000 higher than 1,773 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02706561 · 224 participants · NA
Helping Men Adhere to Sexual Rehabilitation Following Prostate Cancer Surgery
- NCT04140344 · 224 participants · NA
The NOTICE Study: Neurosurgery and OrThopedIcs Communication Evaluation Study Following Lumbar Fusions
- NCT04915183 · 224 participants · Phase 2
Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer
- NCT05519878 · 224 participants · NA
Light Therapy and Occupational Therapy Fatigue Management-Based Intervention for Patients With Genitourinary Cancers
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI